1. Dr. Reddy's Laboratories Ltd., India's third-biggest drugmaker, has made its version of Roche Holding AG's rituximab 50 percent cheaper than the original, allowing more access to the cancer therapy (non-Hodgkin's lymphoma, a blood malignancy).
2. Reddy's released Reditux in Hyderabad, India and also will seek to sell the treatment elsewhere, including the U.S.
3. Reddy's and bigger rivals Ranbaxy Laboratories Ltd. and Cipla Ltd. built billion-dollar businesses copying blockbuster medicines and selling them at a fraction of the price in the U.S. and Europe.
4. They are developing the capability to produce complex drugs, known as biologics, whose sales are growing at 14 times the pace of traditional chemical compounds and are among the most expensive prescriptions.
5. Reddy's Reditux is priced at 20,000 rupees ($486) for a vial, or about half the price Roche charges for Mabthera, which is patent-protected until 2013 and there are no immediate plans to change its price.
The medicine man has come a long way but survives as before by ingenuity.
[Click here for full story at: BLOOMBERG.COM]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment